Open Access
Cell Reports, volume 43, issue 2, pages 113810
Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures
Atsushi Tanaka
1
,
Atsushi Tanaka
1
,
Makiko Ogawa
1
,
Yihua Zhou
2
,
Kensuke Namba
3
,
Kei Namba
3
,
Ronald C Hendrickson
4
,
Matthew Miele
4
,
ZHUONING LI
4
,
David S. Klimstra
5
,
Patrick G Buckley
6
,
Patrick Buckley
6
,
Jeffrey Gulcher
6
,
Julia Y. Wang
7
,
Michael H. Roehrl
8
6
Genuity Science, Boston, MA, USA.
|
7
Curandis, New York, NY, USA.
|
Publication type: Journal Article
Publication date: 2024-02-19
Journal:
Cell Reports
scimago Q1
wos Q1
SJR: 4.279
CiteScore: 13.8
Impact factor: 7.5
ISSN: 22111247, 26391856
General Biochemistry, Genetics and Molecular Biology
Abstract
Metastatic progression of colorectal adenocarcinoma (CRC) remains poorly understood and poses significant challenges for treatment. To overcome these challenges, we performed multiomics analyses of primary CRC and liver metastases. Genomic alterations, such as structural variants or copy number alterations, were enriched in oncogenes and tumor suppressor genes and increased in metastases. Unsupervised mass spectrometry-based proteomics of 135 primary and 123 metastatic CRCs uncovered distinct proteomic subtypes, three each for primary and metastatic CRCs, respectively. Integrated analyses revealed that hypoxia, stemness, and immune signatures characterize these 6 subtypes. Hypoxic CRC harbors high epithelial-to-mesenchymal transition features and metabolic adaptation. CRC with a stemness signature shows high oncogenic pathway activation and alternative telomere lengthening (ALT) phenotype, especially in metastatic lesions. Tumor microenvironment analysis shows immune evasion via modulation of major histocompatibility complex (MHC) class I/II and antigen processing pathways. This study characterizes both primary and metastatic CRCs and provides a large proteogenomics dataset of metastatic progression.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.